| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8828427 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Jun, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6476052 | BRISTOL | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(7 years ago) | |
| US5653517 | BRISTOL | Process and system for determination of friction/slip characteristics of road vehicle tires |
Jul, 2016
(7 years ago) | |
| US5635517 | BRISTOL | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Jul, 2016
(7 years ago) | |
| US8158653 | BRISTOL | Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline |
Aug, 2016
(7 years ago) | |
| US6316471 | BRISTOL | Isoindolines, method of use, and pharmaceutical compositions |
Aug, 2016
(7 years ago) | |
| US8589188 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US6561976 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US6908432 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US8204763 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US6045501 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
| US6561977 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US6315720 | BRISTOL | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct, 2020
(3 years ago) | |
| US8626531 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US8315886 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US6755784 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
| US8735428 | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(11 months ago) | |
| US8673939 | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(11 months ago) | |
|
US8673939 (Pediatric) | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(5 months ago) | |
|
US8735428 (Pediatric) | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(5 months ago) | |
| US8198262 | BRISTOL | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Jun, 2025
(1 year, 1 month from now) | |
|
US8198262 (Pediatric) | BRISTOL | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Dec, 2025
(1 year, 7 months from now) | |
| US9993467 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(6 years from now) | |
| US10555939 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(6 years from now) | |
|
US9993467 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(6 years from now) | |
|
US10555939 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(6 years from now) | |
|
US8828427 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Dec, 2031
(7 years from now) | |
Pomalyst is owned by Bristol.
Pomalyst contains Pomalidomide.
Pomalyst has a total of 27 drug patents out of which 19 drug patents have expired.
Expired drug patents of Pomalyst are:
- US6476052
- US5653517
- US5635517
- US8158653
- US6316471
- US8589188
- US6561976
- US6908432
- US8204763
- US6045501
- US6561977
- US6315720
- US8626531
- US8315886
- US6755784
- US8735428
- US8673939
- US8673939*PED
- US8735428*PED
Pomalyst was authorised for market use on 08 February, 2013.
Pomalyst is available in capsule;oral dosage forms.
Pomalyst can be used as use of pomalidomide while preventing the exposure of a fetus or other contraindicated individual to pomalidomide, use of pomalidomide for the treatment of multiple myeloma, use of pomalidomide to inhibit the secretion of pro-inflammation cytokines, including tumor necrosis factor alpha.
Drug patent challenges can be filed against Pomalyst from 14 November, 2026.
The generics of Pomalyst are possible to be released after 21 December, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-14) | Nov 20, 2023 |
| Orphan Drug Exclusivity(ODE-297) | May 14, 2027 |
| Orphan Drug Exclusivity(ODE-296) | May 14, 2027 |
| Pediatric Exclusivity(PED) | Nov 14, 2027 |
| New Indication(I-707) | Apr 23, 2018 |
| Orphan Drug Exclusivity(ODE-43) | Feb 08, 2020 |
| Orphan Drug Exclusivity(ODE) | Feb 08, 2020 |
| New Chemical Entity Exclusivity(NCE) | Feb 08, 2018 |
Drugs and Companies using POMALIDOMIDE ingredient
NCE-1 date: 14 November, 2026
Market Authorisation Date: 08 February, 2013
Treatment: Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide to inhibit the secretion of pro-inflammation cytokines, including tumor necrosis factor alpha; Use of pomalidomide while ...
Dosage: CAPSULE;ORAL
POMALYST family patents
